What Is Pseudonymization Under GDPR? A Practical Guide 

What Is Pseudonymization Under GDPR? A Practical Guide

Last Updated on July 1, 2026

If you apply pseudonymisation properly, it can be a useful mechanism to enhance the security of personal data and support your overall compliance with the data protection principles. Data protection law doesn’t include a specific definition of risk. “The application of pseudonymisation to personal data can reduce the risks to the data subjects https://homadeas.com/how-artificial-intelligence-will-help-in-construction-in-2024.html concerned.”

• In summary, tokenization can be a powerful tool for both pseudonymization and anonymization, providing an additional layer of security and privacy to sensitive data while preserving data utility for analysis and processing.
• This type of risk-based approach is grounded in statistical methods — with a healthy dose of realism — and tends to be favored by regulators in multiple jurisdictions, from the U.S.
• Flow diagram of the selection process for pseudonymization tools (based on )
• An inadequate level of pseudonymisation does not meet the legal definition of pseudonymisation in data protection law, even if the technique you use may fit under existing technical meanings of the term.
• Following a structured search and selection process, we assessed the identified pseudonymization tools based on different properties.

To force records into equivalence classes, one would need to apply such broad generalization (e.g., reducing detailed query topics to very high-level categories) or suppress so much data that the resulting dataset loses significant analytical value. The landscape includes various related but distinct concepts, each carrying different technical implications and legal weight. The report concludes by synthesizing these findings to summarize the core privacy challenges, risks, and ongoing debates surrounding the de-identification of massive search query datasets. The goal is to enable data analysis, research, and sharing while mitigating privacy harms and complying with legal and ethical obligations.

You should identify roles and responsibilities of any party involved in the pseudonymisation process. You should ensure that once you implement pseudonymisation, you mitigate any risk of unauthorised reversal of it. An inadequate level of pseudonymisation does not meet the legal definition of pseudonymisation in data protection https://bussinessfair.info/ensuring-compliance-through-rigorous-financial-auditing.html law, even if the technique you use may fit under existing technical meanings of the term. The DPA 2018’s explanatory notes provide further information on how the re-identification offences apply to pseudonymised data (external link)

Stronger position during regulatory scrutiny

DICOM Pseudonymization engines must detect these regions using pattern recognition and apply destructive overlay masks. In pseudonymization, the original Study Instance UID and Series Instance UID must often be replaced with new, consistent pseudonyms to prevent cross-referencing while maintaining internal data integrity. Why is pseudonymization preferred over anonymization in clinical trials? The process targets specific DICOM Tags like Patient Name (0010,0010) and Medical Record Number (0010,0020), replacing their values with generated codes. Unlike DICOM Anonymization, which irreversibly strips all links, pseudonymization retains a mapping table or cryptographic key.

• Replaces data values with random tokens stored in a secure vault.
• This distinction is critical under regulations like GDPR, where anonymized data falls outside the scope of data protection law, while pseudonymized data remains regulated personal information.
• The authors report that their methods work directly on raw user content across arbitrary platforms, not only on structured datasets.
• Unlike pseudonymization, this profile specifies exactly which DICOM Tags must be removed or blanked (e.g., Patient Name 0010,0010, Patient ID 0010,0020) to satisfy the HIPAA Safe Harbor method.
• The LRX and EMR data therefore had to be treated as personal data subject to GDPR and French data protection law.

Additionally, tokens can be https://business-exclusive.com/autoclavable-laboratory-fermenter-and-bioreactor-from-brs-biotech-main-advantages.html easily reversed, allowing the original data to be accessed when needed. This means that the data can still be used for business purposes, such as analytics while protecting the privacy of the data subjects. The choice between pseudonymization and anonymization depends on the specific needs of the organization and the data they are working with.